Minimum 2mm boundary
Easy to Adopt
Dental implants carry a high risk of iatrogenic complications associated with drill penetration of critical anatomic structures (i.e. the alveolar nerve and the sinus cavities). A spinout of RyTek Medical, the OsteoSmartSense Drill is a smart dental drill capable of gauging tissue bioimpedance at the tip of the bit and providing real-time feedback to oral surgeons about proximity to high-risk anatomic features during drilling.
Our patented OsteoSmartSense Drill System integrates electrical property sensing into a standard clinical dental implant drill. Based on the large impedance contrast between cancellous and cortical bone and our expertise in sensing tissue impedance, we are uniquely positioned to develop and commercialize this technology.
The OsteoSmartSense Team
Ryan Halter, Ph.D.
CEO and Co-founder
Ryan is the Co-founder and Chief Executive Officer of OsteoSmartSense. He is also an Associate Professor of Engineering at Dartmouth’s Thayer School of Engineering and an Adjunct Associate Professor of Surgery at Dartmouth’s Geisel School of Medicine. Dr. Halter has been working with EIS for over sixteen years and has developed bioimpedance-sensing devices for a variety of clinical applications. He has extensive experience with biomedical instrumentation, electrical impedance tomography and spectroscopy, medical sensing, tissue bioimpedance, and medical robotics.
Michael Salin, D.M.D.
CMO and Co-founder
Mike is Chief Medical Officer at OsteoSmartSense and a board certified, practicing oral and maxillofacial surgeon with over 15 years of clinical practice. As a full-time practicing surgeon Dr. Salin has observed discrepancy in the radiographic location of important anatomic structures and the challenges presented in determining their location real-time while surgically placing an implant. Using the endodontic apex locator as a model, Dr. Salin came up with the concept and goal of having a quantitative, “real-time” measuring device to assist surgeons in performing implant surgery safely and with a reliable degree of certainty. He is also an Associate Professor of Oral and Maxillofacial Surgery at Temple University School of Medicine.
Alicia Everitt, Ph.D.
Alicia is Chief Technology Officer at OsteoSmartSense. Dr. Everitt received her Ph.D. in Biomedical Engineering from Dartmouth College and has expertise in bioimpedance-based technologies and medical device development and design. Dr. Everitt also trained as a PhD Innovation Fellow, which included independently managing an annual research budget, completing complementary MBA coursework including patent law, market evaluation and startup enterprise planning, and completing a surgical specialty year of medical school clinical rotations. She has industry experience in surgical technologies (Medtronic), as well as experience in a startup (Poewr4Flight) where she was the fourth employee and direct manager of multiple project designations—several of which are now in production.
The OsteoSmartSense Board
Get to Know Us
Robert Segal, M.D., F.A.C.P.
Robert has over 30 years of medical and pharmaceutical experience including serving in the role of Chief Medical Officer and has been broadly responsible for the design and execution of numerous multi-national, multi-site clinical Phase 2 through Phase 3 and nonclinical studies. Dr. Segal has served as Senior Vice President (SVP), of Discovery Laboratories, Inc./ Windtree Therapeutics, Inc. (NASDAQ). Previously, he served at Merck Laboratories in the position of Director, Cardiovascular Clinical Research. Prior to joining Merck, he was an Assistant Professor of Medicine in the Division of Nephrology at UCLA School of Medicine and served as an advisor to the Biotechnology Program at Northwestern University. Dr. Segal has extensive experience with small health-focused business and has successfully been awarded over $15M in SBIR/STTR funding as PI (including Fast Track, Direct-to-Phase 2, and Phase 2B Bridge / Small Market awards).
David Lopez, Esq., C.P.A.
David has over 30 years as an attorney, financial officer and transactional professional in life sciences and high-technology. He has extensive experience in all rounds of fundraising (from seed through preferred and mezzanine rounds, IPOs, and secondary offerings), corporate strategic and business development matters and merger and acquisition (M&A) transactions. He serves as CFO, General Counsel and heads up business development at Immunicom, Inc., a San Diego-based immuno-oncology startup. Previously, he has was Sr. Promotional Compliance/Regulatory Attorney at Otsuka and Sr. Attorney at a Cravath Swain law firm spinoff specializing in life sciences, biotechnology, and medical device. Mr. Lopez also has investment banking experience at Drexel Burnham Lambert and consulting / auditing experience in “Big Four” public accounting.